FDA Class II Recall Targets 3,744 Bottles of Macleods Pharma Blood Pressure Meds for Dissolution Failures

Key points

• The recall covers 3,528 30-count bottles from lot 12251163A and 216 90-count bottles from lot 12251163B, both expiring May 31, 2027.
• The FDA classified the recall as Class II on Oct. 26, 2026, indicating the medication may cause temporary or medically reversible adverse health consequences.
• The recall was initiated on Oct. 7, 2026, after the medication failed to meet quality standards, specifically failing to dissolve as required during testing.
• The affected medication is a generic triple-combination containing olmesartan medoxomil, amlodipine, and hydrochlorothiazide.
• Patients are advised to check their lot numbers and consult healthcare providers before stopping treatment, as brand-name versions are unaffected.

Background

This recall follows a pattern of quality issues with generic blood pressure medications. In June 2026, Inventia Healthcare recalled certain lots of chlorthalidone tablets, followed by a separate recall on Sept. 3, 2026, which the FDA classified as Class II on Sept. 17, 2026. The current recall highlights ongoing concerns about dissolution testing in generic medications.

Why it matters

The recall affects a widely used generic blood pressure medication, potentially impacting thousands of patients. The Class II classification indicates that while the issue is serious, it is unlikely to cause permanent health consequences. Patients should be vigilant about checking lot numbers and consulting their doctors to ensure they receive proper treatment.

What to watch

The FDA will continue to monitor the recall and may issue further updates. Patients should check their medication lot numbers and consult their healthcare providers if they have concerns. The FDA may also investigate the root cause of the dissolution failures to prevent future issues.